KRAS and colonic neoplasm: Analyzing these reports, we found that a glycine to valine mutation at codon 12 of the KRAS gene, the same mutation that we describe in this report, associates with poor survival in colon cancer [25] suggesting that this mutation may represent a marker of tumor aggressiveness, perhaps in thyroid cancer as well.